Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Metabolic Drug Interactions between Angiogenic Inhibitor, Tnp-470 and Anticancer Agents in Primary Cultured Hepatocytes and Microsomes

Laurent Placidi, Erika Cretton Scott, Devin Eckoff, Steven Bynon and Jean-Pierre Sommadossi
Drug Metabolism and Disposition May 1999, 27 (5) 623-626;
Laurent Placidi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erika Cretton Scott
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Devin Eckoff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Bynon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Pierre Sommadossi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The potential metabolic drug interactions between TNP-470, a potent inhibitor of angiogenesis, and several commonly used anticancer agents, such as cyclophosphamide, taxol, and minocycline, were investigated in vitro using primary cultured hepatocytes and microsomes of rhesus monkeys. After incubation of hepatocytes with 5 μM [3H]TNP-470, rapid and extensive formation of six metabolites was observed, with M-II and M-IV being the predominant metabolites. After 30 min of incubation in the presence of 250 μM cyclophosphamide, concentrations of unchanged TNP-470 and M-IV were increased with values of 1.00 ± 0.02 and 1.49 ± 0.01 μM compared with control values of 0.67 ± 0.09 (p = .02), 1.39 ± 0.03 μM (p < .01), respectively. In contrast, the concentration of M-II was substantially decreased from 1.69 ± 0.86 to 1.02 ± 0.16 μM (p = .01). Combination of taxol with TNP-470 led to a 50% decrease of M-II levels (p < .01), whereas unchanged TNP-470 and M-IV levels were increased by at least 2.5-fold compared with control (p = .08 and 0.01). Exposure of cells to TNP-470 with 250 μM minocycline had no effect on TNP-470 metabolism in monkey hepatocytes. In vitro studies with isolated monkey liver microsomes confirmed these drug–drug metabolic interactions detected at the cellular level. A detailed understanding of the potential drug interactions in TNP-470 metabolism occurring with taxol or cyclophosphamide is critical to fully elucidate the potentiation of the antitumor activity observed in vivo after coadministration of these two agents with TNP-470.

Footnotes

  • Send reprint requests to: Dr Jean-Pierre Sommadossi, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Volker Hall G020, Birmingham, AL 35294-0019. E-mail: Jean-Pierre.Sommadossi{at}ccc.uab.edu

  • This work was supported in part by United States Public Health Service Grant AI-32775 by an unrestricted grant from TAP Pharmaceuticals, Inc. and by the University of Alabama Liver Center. J.-P. Sommadossi was a recipient of a faculty Research Award from the American Cancer Society.

  • Abbreviations used are::
    [3H]TNP-470
    (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-2-butenyl)oxiranyl]-1-[6[3H]oxaspiro-[2.5]-oct-6-yl-(chloroacetyl)carbamate
    FCS
    fetal calf serum
    • Received April 16, 1998.
    • Accepted January 11, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 27 (5)
Drug Metabolism and Disposition
Vol. 27, Issue 5
1 May 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Metabolic Drug Interactions between Angiogenic Inhibitor, Tnp-470 and Anticancer Agents in Primary Cultured Hepatocytes and Microsomes
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Metabolic Drug Interactions between Angiogenic Inhibitor, Tnp-470 and Anticancer Agents in Primary Cultured Hepatocytes and Microsomes

Laurent Placidi, Erika Cretton Scott, Devin Eckoff, Steven Bynon and Jean-Pierre Sommadossi
Drug Metabolism and Disposition May 1, 1999, 27 (5) 623-626;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Metabolic Drug Interactions between Angiogenic Inhibitor, Tnp-470 and Anticancer Agents in Primary Cultured Hepatocytes and Microsomes

Laurent Placidi, Erika Cretton Scott, Devin Eckoff, Steven Bynon and Jean-Pierre Sommadossi
Drug Metabolism and Disposition May 1, 1999, 27 (5) 623-626;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results and Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Adipocyte PXR does not play an essential role in obesity.
  • CYP3A-mediated oxidation of DABE and BIBR0951
  • Biodistribution of Lipid in Rats
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics